Moroccan Society of Genomics and Human Genetics (SM2GH) and Spanish Society of Gene and Cell Therapy (SETGyC) Forge Strategic Collaboration
The Moroccan Society of Genomics and Human Genetics (SM2GH) and the Spanish Society of Gene and Cell Therapy (SETGyC) are thrilled to announce a groundbreaking collaborative agreement, signed on Friday, October 20th, 2023, to advance scientific and educational cooperation between the two esteemed organizations.
This historic collaboration aims to foster partnerships between the SM2GH and the SETGyC, focusing on the pivotal domains of human genetics, immunogenetics, genome editing, and the development of gene and cell therapies. At the core of this alliance is a shared commitment to nurturing the growth and development of young researchers, regardless of their Moroccan or Spanish origins.
Key objectives of this collaborative agreement include:
- Student and Young Researcher Training: Both societies are dedicated to equipping the next generation of scientists with the knowledge and skills needed in the fields of genome editing, gene therapy, and cell therapy.
- Training of Trainers: The collaboration will facilitate the training of trainers in the specialized areas of genome editing and gene and cell therapy, ensuring a sustainable knowledge transfer process.
- Joint Educational Initiatives: SM2GH and SETGyC will co-organize a series of courses, workshops, and conferences that cater to the scientific interests of both societies. These events will serve as hubs for knowledge exchange and collaboration, bringing together experts from both Morocco and Spain.
The implementation of this agreement will also be facilitated through the Cost Action CA21113, “Gene Editing for the Treatment of Human Diseases” (GenEHumDi). By leveraging this initiative, Professor Khalid Sadki, the Founder and President of SM2GH, will embark on a Short Term Scientific Mission (STMS) to Donostia, Spain, further strengthening the bonds of cooperation between the two societies. The meeting in Donostia witnessed the historic agreement being co-signed by Professor Ander Izeta, President of SETGyC, and Professor Khalid Sadki, the visionary leader behind SM2GH.
The signing of this collaborative agreement represents a significant milestone in the pursuit of scientific excellence, cross-cultural understanding, and the advancement of human genetics, genome editing, and gene and cell therapy. Both SM2GH and SETGyC are committed to nurturing the talent of young scientists and researchers in Morocco and Spain, ushering in a new era of scientific progress and innovation.
For media inquiries and more information, please contact: the Cost Action CA21113 SCC Coordinator.
About SM2GH
The Moroccan Society of Genomics and Human Genetics (SM2GH) is a leading scientific organization dedicated to advancing research and education in the fields of genomics and human genetics in Morocco. Founded by Professor Khalid Sadki, SM2GH is committed to promoting scientific excellence, fostering collaboration, and facilitating knowledge exchange among professionals and students in Morocco and beyond. More information in its website: https://www.sm2gh.ma/
About SETGyC
The Spanish Society of Gene and Cell Therapy (SETGyC) is a distinguished institution at the forefront of research and development in gene and cell therapies in Spain. Led by President Professor Ander Izeta, SETGyC is focused on driving scientific innovation, fostering educational initiatives, and facilitating partnerships within the field of gene and cell therapy. Find more in : https://www.setgyc.es/
About GenEHumDi
The GENome Editing for the treatment HUMan DIseases (GenEHumdi|COST Action 21113) is an EU funded initiative to fuel promotion of laboratory proven Genome Editing technologies towards clinical implementation. Such therapeutic strategies requires coordination and of basic, applied, industrial, and pharmaceutical scientist in addition to industry and regulatory agencies. This initiative is currently chaired by prof, Karim Benabdel and Alessia Cavazza.